The stock of Bausch Health Companies Inc (NYSE:BHC) last traded at $7.34, up 3.67% from the previous session.
Data from the available sources indicates that Bausch Health Companies Inc (NYSE:BHC) is covered by 7 analysts. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $16.00 and a low of $6.00, we find $8.00. Given the previous closing price of $7.08, this indicates a potential upside of 12.99 percent. BHC stock price is now -7.28% away from the 50-day moving average and -8.00% away from the 200-day moving average. The market capitalization of the company currently stands at $2.67B.
In total, 4 analysts have assigned it a hold rating, and 2 have given it a buy rating. Brokers who have rated the stock have averaged $9.50 as their price target over the next twelve months.
With the price target enhanced from $9 to $16, Jefferies Upgraded its rating from Hold to Buy for Bausch Health Companies Inc (NYSE: BHC).
In other news, Carson Seana, EVP, General Counsel sold 6,685 shares of the company’s stock on Sep 06. The stock was sold for $55,352 at an average price of $8.28. Upon completion of the transaction, the EVP, General Counsel now directly owns 385,213 shares in the company, valued at $2.83 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 28, EVP, General Counsel Carson Seana sold 292 shares of the business’s stock. A total of $2,721 was realized by selling the stock at an average price of $9.32. This leaves the insider owning 359,185 shares of the company worth $2.64 million. A total of 2.16% of the company’s stock is owned by insiders.
With an opening price of $7.35 on Thursday morning, Bausch Health Companies Inc (NYSE: BHC) set off the trading day. During the past 12 months, Bausch Health Companies Inc has had a low of $5.57 and a high of $10.23. The fifty day moving average price for BHC is $7.90 and a two-hundred day moving average price translates $7.98 for the stock.
The latest earnings results from Bausch Health Companies Inc (NYSE: BHC) was released for Jun, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.82, beating analysts’ expectations of $0.78 by 0.04. This compares to -$0.38 EPS in the same period last year. The company reported revenue of $2.17 billion for the quarter, compared to $1.97 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 10.17 percent. For the current quarter, analysts expect BHC to generate $2.15B in revenue.
Bausch Health Companies Inc(BHC) Company Profile
Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was incorporated in 2013 and is headquartered in Laval, Canada.
